Trial Profile

A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-149 for the Treatment of Diabetic Macular Edema (DME)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Oct 2019 According to an Oxurion media release, data from this study were presented at major Retinal Conferences in Europe and the US including 19th Congress of European Society of Retina Specialists (EURETINA), Retina Society Annual Meeting and the American Academy of Ophthalmology Annual Meeting (AAO).
09 Oct 2019 Results presented in an Oxurion media release.
09 Oct 2019 According to an Oxurion media release, clinical update will be presented at upcoming Ophthalmology Innovation Summit (OIS) meeting which will be held on 10th October 2019, at the Hilton San Francisco Union Square.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com